Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
By W. Symmans, F. Peintinger, C. Hatzis, Radhika Rajan, H. Kuerer, V. Valero, Lina Assad, A. Poniecka, Bryan T. J. Hennessy, M. Green and 7 more. Journal of Clinical Oncology, 2007
1,500 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/08addcf7df10bb48ebbffdb491e86f7a31254830
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Pathology and Forensic Medicine
In Surgery
Citations in the corpus
- Breast Tumor Cellularity Assessment using Deep Neural Networks (2019, methodology): “and the quality and reliability might be also be affected by high inter-observer variability even among senior pathologists. This potentially may affect prognostic power assessment in clinical trials [4]. The subjectivity in visual tissue assessment motivates the use of computer-aided methods to imp”
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013, methodology): “also evaluated the residual breast cancer burden (RCB) index (9), a postchemotherapy pathologic measure that considers the size and invasive proportion of the primary tumor and the number and size of nodal metastases, and has potential to predict the clinical outcome after neoadjuvant chemotherapy m”
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. (2020, neutral): “HR positive/ERBB2 negative 30 (17-43) 13 (7-19) >99.”
- Deep neural network models for computational histopathology: A survey (2019, background): “There is, however, considerable inter-pathologist variability, and some systems that require quantitative analysis, for example the residual cancer burden index (Symmans et al., 2007), are too time-consuming to use in a routine clinical setting.”
- Triple-negative breast cancer--current status and future directions. (2009, methodology): “Response to neoadjuvant chemotherapy measured either by dichotomization into pCR/residual disease (RD) or as a fourtired response score [101] provided significant prognostic information among patients with BLBC: patients with excellent response to neoadjuvant chemotherapy had an excellent relapsefre”
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016, methodology): “Determination of pathologic response Pathologic response was assessed centrally in all three trials using the residual cancer burden (RCB) index (26).”
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015, background): “For nonpCRs, pathologists were asked to record residual cancer burden (RCB).(13)”
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. (2017, neutral): “All All Local event 9 (4) 18 (7) 7 (2) 34 (4) 8 (6) 0 3 (2) 45 (4) RFS event 65 (30) 86 (33) 90 (26) 241 (29) 52 (39) 29 (14) 14 (7) 336 (29) Distant event 49 (22) 71 (27) 67 (20) 187 (23) 40 (30) 28 (14) 11 (5) 230 (20) Deceased 51 (23) 72 (28) 63 (18) 186 (23) 45 (34) 17 (8) 10 (5) 258 (22) Median”
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020, background): “However, retrospective studies have suggested that OS correlates with amuch larger spectrum of RVT, implying that if assessments beyond pCR and MPR could be performed, prognostication could potentially be available for all patients (12, 63).”